TipRanks
Advertisement
Advertisement

DE:IF0 Stock Latest News

InflaRx initiated with a Buy at Needham
The FlyInflaRx initiated with a Buy at Needham
16d ago
IFRX
InflaRx files $250M mixed securities shelf
PremiumThe Fly
InflaRx files $250M mixed securities shelf
2M ago
IFRX
InflaRx Files Mid‑Year 2026 Unaudited Results in SEC Form 6‑K
PremiumCompany Announcements
InflaRx Files Mid‑Year 2026 Unaudited Results in SEC Form 6‑K
2M ago
6K
IFRX
InflaRx Moves to Broaden AAV Strategy in Europe After EMA Setback for Tavneos
PremiumCompany Announcements
InflaRx Moves to Broaden AAV Strategy in Europe After EMA Setback for Tavneos
3M ago
6K
IFRX
InflaRx upgraded to Strong Buy from Outperform at Raymond James
PremiumThe Fly
InflaRx upgraded to Strong Buy from Outperform at Raymond James
5M ago
IFRX
InflaRx price target raised to $8 from $6 at H.C. Wainwright
PremiumThe FlyInflaRx price target raised to $8 from $6 at H.C. Wainwright
5M ago
IFRX
InflaRx Raises $150 Million in Underwritten Share Offering Filed in Early May 2026
Premium
Company Announcements
InflaRx Raises $150 Million in Underwritten Share Offering Filed in Early May 2026
5M ago
6K
IFRX
InflaRx to develop izicopan in AAV
Premium
The Fly
InflaRx to develop izicopan in AAV
5M ago
IFRX
InflaRx Refocuses Izicopan on Vasculitis and Renal Diseases With Funding Runway to 2029
PremiumCompany Announcements
InflaRx Refocuses Izicopan on Vasculitis and Renal Diseases With Funding Runway to 2029
5M ago
6K
IFRX
InflaRx Files Q1 2026 Financials with SEC via Form 6-K
PremiumCompany Announcements
InflaRx Files Q1 2026 Financials with SEC via Form 6-K
5M ago
6K
IFRX
InflaRx Highlights Favorable Safety-Signal Data for Izicopan in New Preclinical Study
PremiumCompany Announcements
InflaRx Highlights Favorable Safety-Signal Data for Izicopan in New Preclinical Study
5M ago
6K
IFRX
InflaRx announces new izicopan pre-clinical data
PremiumThe Fly
InflaRx announces new izicopan pre-clinical data
5M ago
IFRX
InflaRx Regains Nasdaq Minimum Bid Price Compliance, Securing Listing Status
PremiumCompany AnnouncementsInflaRx Regains Nasdaq Minimum Bid Price Compliance, Securing Listing Status
5M ago
6K
IFRX
InflaRx assumed with an Outperform at Oppenheimer
Premium
The Fly
InflaRx assumed with an Outperform at Oppenheimer
5M ago
IFRX
InflaRx Shareholders Approve Capital, Governance Changes and 2026 Incentive Plan at April AGM
Premium
Company Announcements
InflaRx Shareholders Approve Capital, Governance Changes and 2026 Incentive Plan at April AGM
5M ago
6K
IFRX
InflaRx Highlights New Izicopan Data Showing No CYP3A4 Time-Dependent Inhibition
PremiumCompany Announcements
InflaRx Highlights New Izicopan Data Showing No CYP3A4 Time-Dependent Inhibition
6M ago
6K
IFRX
InflaRx announces new izicopan in vitro findings
PremiumThe Fly
InflaRx announces new izicopan in vitro findings
6M ago
IFRX
InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP
PremiumCompany Announcements
InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP
6M ago
6K
IFRX
InflaRx presents vilobelimab data
PremiumThe Fly
InflaRx presents vilobelimab data
6M ago
IFRX
InflaRx price target lowered to $14 from $22 at Guggenheim
PremiumThe FlyInflaRx price target lowered to $14 from $22 at Guggenheim
6M ago
IFRX
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027
Premium
Company Announcements
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027
6M ago
6K
IFRX
InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year
Premium
The Fly
InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year
6M ago
IFRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >